FindTrial
Sign In

Study for biomarkers in predicting the efficacy of PD-1 monoclonal antibody in gastrointestinal cancer

Establishment of biomarker combination model predicting the efficacy of PD-1 monoclonal antibody and its application in colorectal cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029121
Enrollment
Unknown
Registered
2020-01-14
Start date
2018-09-01
Completion date
Unknown
Last updated
2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal cancer

Interventions

Gold Standard:Clinical outcome
Index test:multi-parameter&#32
combination&#32
model

Sponsors

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with gastrointestinal cancer treated with pd-1 monoclonal antibody

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

MeasureTime frame
SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactJun Zhang

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

jameszhang2000@163.com+86 13515813731

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026